Table 1

Clinical Characteristics and Patient-Based Study Data

LDL Chol (mmol/liter)
Pt No./Age (yr)GroupPrestudy EventBaseDuringΔMSD (mm)ΔMOD (mm)ΔST Time (s)ΔHMTT (s)
1/29L/12.095.670.390.20−4200.17
2/59MI/C7.013.740.140.15−0.09
3/67MA/C6.623.900.110.0500.97
4/59MI/7.054.260.060.041.46
5/52MI/5.943.58−0.14−0.12−1.58
6/43LNQ/5.452.65−0.30−0.24−30−0.19
7/69MI/CP6.283.060.11−0.09
8/67MI/P6.512.69−0.42−0.252.57
9/46L/6.633.00−0.12−0.09−360−0.62
10/65L/6.973.760.050.07−0.14
11/46LI/C7.172.760.230.19
12/46MA/6.113.57−0.08−0.0860−0.75
13/66LI/6.972.14−0.08−0.16−299
14/58M/C6.433.470.070.12
15/53LI/C6.801.98−0.09−0.14−360−0.38
16/40M/9.905.320.260.201200.00
17/58LI/C6.712.030.00−0.13−60−0.51
18/52LA/C11.365.22−0.33−0.0623−0.06
19/47MI/C12.865.62−0.29−0.09−0.41
20/30LA/C10.753.69−0.03−0.06−3300.41
21/50LA/C7.603.120.040.20
22/45MNQ/9.204.950.070.100−0.21
23/56MA/C11.654.930.170.07−0.62
24/44MI/6.593.430.180.06360−0.14
25/57LI/P7.062.09−0.02−0.06−165−1.09
26/56MI/C5.922.760.080.05−120−1.58
27/50LI/10.843.36−0.06−0.04−0.30
28/42LA/7.602.510.200.170.45
29/63*LIA/C6.572.09−1.27
30/49M/CP8.304.290.000.03−1.50
31/52MI/7.604.14−0.010.02600.22
32/54LI/C6.282.100.100.09−240−1.51
33/42L/7.032.00−0.14−0.11−0.50
34/56MA,A/C6.683.26−0.06−0.0800.59
35/56LA/C6.662.03−0.11−0.13−55−1.34
36/46L/8.844.020.000.03−67−0.36
37/49MNQ/7.314.480.07−0.01
38/50MA/CP5.832.790.24
39/62LI/PC6.362.59−0.030.03−60−1.37
40/54LI/6.382.270.03−0.01−880.57
41/66MA/7.163.16−0.02−0.07−60
42/42MI/P13.909.290.200.155−0.03
  • * Patient underwent repeat coronary artery bypass graft surgery (C) 12 weeks after start of low density lipoprotein (LDL) apheresis and died postoperatively due to low cardiac output. A = anterior myocardial infarction; Base = baseline; During = mean LDL cholesterol level during trial (for LDL apheresis group [L], data are time-averaged values [for conversion to mg/dl, multiply by 38.7]); I = inferior myocardial infarction; M = medication; NQ = non-Q wave myocardial infarction; P = percutaneous transluminal coronary angioplasty; Pt = patient; ΔHMMT = change in hyperemic mean transit time; ΔMOD = change in minimal obstruction diameter (baseline vs. follow-up); ΔMSD = change in mean segment diameter from quantitative coronary angioplasty measurements (baseline vs. follow-up); ΔST Time = change in time to 1-mm (0.1 mV) ST segment depression.